杜瓦卢马布
胆道癌
吉西他滨
耐受性
顺铂
医学
肿瘤科
胆道
内科学
癌症
化疗
不利影响
无容量
免疫疗法
作者
Margherita Rimini,Lorenzo Fornaro,Mario Domenico Rizzato,Lorenzo Antonuzzo,Federico Rossari,Tomoyuki Satake,Hanne Vandeputte,Caterina Vivaldi,Tiziana Pressiani,Jessica Lucchetti,Jin Won Kim,Oluseyi Abidoye,Ilario Giovanni Rapposelli,Stefano Tamberi,Fabian Finkelmeier,Guido Giordano,Federico Nichetti,Hong Jae Chon,Chiara Braconi,Chiara Pirrone
标识
DOI：10.1016/j.ejca.2024.114199
摘要
The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combination's real-world efficacy and tolerability, we conducted a global multicenter retrospective analysis of its first-line treatment outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
张欢馨
woshi123
v0id
yzy
cdercder
Kao
22336
云城
整齐的慕卉
yjh123
科研狗
乐空思
xing_xing
lixinglei
aaaa
丰富语蕊
XLL小绿绿
GingerF
Oracle
OK
皖公网安备34019202002308
